Uppsala, Sweden, 2012-09-06 09:00 CEST (GLOBE NEWSWIRE) --
MUMS DESIGNATION FOR DOXOPHOS® VET
FIRST QUARTER May 1 – July 31, 2012
- Consolidated Net sales amounted to € 0 thousand (107) [1]
- Operating income amounted to € -2,196 thousand (-1,841)
- Net income after tax amounted to € -2,315 thousand (-1,828)
- Earnings per share amounted to € -0.04 (-0.04)
- Comprehensive income amounted to € -2,315 thousand (-1,828)
- FDA grants MUMS designation for Doxophos® Vet
- Oasmia submits application to the FDA for conditional approval of Paccal® Vet for treatment of mammary tumors in dogs.
- Oasmia submits application to the FDA for conditional approval of Paccal® Vet for treatment of squamous cell carcinoma in dogs
- Oasmia and Orion terminate the collaboration for Paccal® Vet.
- Nexttobe AB extends its commitment in Oasmia through a MSEK 65 loan
EVENTS AFTER CLOSING DAY
- Oasmia has initiated the application process for market approval of Paclical®
[1] The numbers in parentheses concerns results for the corresponding period previous year
Weine Nejdemo, CFO, Tel: +46 18 50 54 40 e-mail: info@oasmia.com www.oasmia.com
